Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ernexa Therapeutics Inc.BTX · Entity 8278 | Director | August 01, 2022 | August 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ernexa Therapeutics Inc.
Report date August 01, 2022 · Filed August 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.49 · Expires 2032-08-01 | Direct | 95,100 |
Reported balance
After 2022-08-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-01 · Grant · Acquired 95,100 · Balance 95,100 F1: The stock option vests and becomes exercisable over one year (subject to continued service), with 25% of the shares vesting every three months from the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.49 · Expires 2032-08-01 | Direct | 165,800 |
Reported balance
After 2022-08-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-01 · Grant · Acquired 165,800 · Balance 165,800 F2: The stock option vests and becomes exercisable over two years (subject to continued service), with 1/3 of the shares vesting on the grant date and the remaining shares vesting in 24 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable over one year (subject to continued service), with 25% of the shares vesting every three months from the grant date.
F2: The stock option vests and becomes exercisable over two years (subject to continued service), with 1/3 of the shares vesting on the grant date and the remaining shares vesting in 24 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2022 Filed Aug 4, 2022 00:01 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option (right to buy) · Derivative | 165,800 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001140361-22-028094 · form4.xml · derivative · entry 2 Fiore Gregory · CIK 0001931959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,800 Underlying: Common Stock, par value $0.005 per share · 165,800 shares Expires 2032-08-01 F2 · derivative.exercise_date: The stock option vests and becomes exercisable over two years (subject to continued service), with 1/3 of the shares vesting on the grant date and the remaining shares vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| August 01, 2022 Filed Aug 4, 2022 00:01 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option (right to buy) · Derivative | 95,100 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001140361-22-028094 · form4.xml · derivative · entry 1 Fiore Gregory · CIK 0001931959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,100 Underlying: Common Stock, par value $0.005 per share · 95,100 shares Expires 2032-08-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable over one year (subject to continued service), with 25% of the shares vesting every three months from the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.